3. Sept. 20194 Min.Case Study Origenis GmbH: With Small Molecules against Neurodegenerative DiseasesSeptember 03, 2019 Mithilfe ihrer KI-basierten Small Molecules Technologie schafften es Michael Almstetter und seine zwei Mitstreiter...
4. Juni 20192 Min.Origenis GmbH Announces Research Collaboration with U.S. Cancer CenterJune 04, 2019 Origenis AI Discovery Platform to Identify and Optimize Small Molecule Preclinical Development Candidates for Glioblastoma...
16. Mai 20191 Min.Gateway to Biotech: Top researchers met industry experts in the Faculty Club at IZBMay 16, 2019 Michael Almstetter, CEO Origenis GmbH, explained what can be learned from progress in oncology in order to develop new...